https://doi.org/10.55788/2c99306b
“OFs are a rare but devastating complication of AF,” said Prof. Roland Tilz (University Heart Center Lübeck, Germany) [1]. “Currently, data on the incidence, management, and outcomes of OF is sparse.” Thus, the POTTER-AF study (NCT05273645) aimed to investigate the real-world incidence, management, and outcomes of OF in patients with AF who underwent catheter ablation [1,2].
In total, 214 centres in 35 countries performed 553,729 procedures; 138 cases of OF were detected, resulting in an incidence of 0.025% in the study population. Furthermore, the risk of OF was higher in those undergoing radiofrequency ablation compared with those receiving cryoballoon ablation (0.038% vs 0.0015%; P<0.001). Prof. Tilz mentioned that the median time to symptom onset was 18 days and that the median time to OF diagnosis was 21 days. “Fever, chest pain, neurological symptoms, and odynophagia were the most common symptoms,” he added. The most common delayed complication was severe sepsis, occurring in more than 50% of the patients with OF. Additionally, approximately 25% of the patients suffered from a cerebrovascular event, and 1 out of 5 patients had a cardiac arrest.
“The outcomes for OF are abysmal, with a mortality rate of 65.8%,” emphasised Prof. Tilz. “Only 15.4% of the patients survive without sequela.” Importantly, the death rate is much higher in patients who were treated conservatively (90%) than in patients who underwent endoscopic treatment (56%) or surgical treatment (52%). Finally, the use of an oesophageal temperature probe and the type of anaesthesia (i.e. conscious sedation) were associated with better survival outcomes.
“Thus, surgical or endoscopic intervention is mandatory to improve the survival outcomes in patients with OF,” concluded Prof. Tilz.
- Tilz RR, et al. Prognosis following oesophageal fistula formation in patients undergoing catheter ablation for AF: The POTTER AF Study. Late-Breaking Science Day 1, EHRA 2023, 16–18 April, Barcelona, Spain.
- Tilz RR, et al. Eur Heart J. 2023;Apr 16.DOI: 10.1093/eurheartj/ehad250.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« MANIFEST-PF: Good results for the pentaspline PFA catheter Next Article
Solid results for long-term therapy of UC with filgotinib »
« MANIFEST-PF: Good results for the pentaspline PFA catheter Next Article
Solid results for long-term therapy of UC with filgotinib »
Table of Contents: EHRA 2023
Featured articles
CEASE-AF meets primary endpoint in persistent AF
ANTWERP score selects HF patients for AF ablation
Ablation for Atrial Fibrillation
Surgery saves lives in patients with oesophageal fistula
MANIFEST-PF: Good results for the pentaspline PFA catheter
POWER FAST III: High-power, short-duration radiofrequency ablation for AF
High-power, short-duration ablation linked to a higher stroke risk
Early or delayed ablation for AF?
CEASE-AF meets primary endpoint in persistent AF
Promising results for Marshall Plan ablation strategy
Updates on Devices
Can ICD-EG-derived information improve ventricular tachycardia ablation outcomes?
Prolonged ECG monitoring detects relevant arrhythmias in HCM
Does adaptive pacing work in patients with HF, LBBB, and intact AV conduction?
Can we identify patients who may not benefit from ICD therapy?
Miscellaneous
Statins display benefits for AF patients in a large population-based study
ANTWERP score selects HF patients for AF ablation
Epicardial ablation successful in Brugada syndrome
Highly increased risk of arrhythmias after mechanical ventilation for COVID-19
Related Articles
April 1, 2021
Infliximab reduces potency of first vaccine dose
November 9, 2021
Breathing techniques contributed to COVID-19 recovery
December 18, 2020
COVID-19 far more deadly than seasonal flu, large study confirms
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com